prmt5 inhibitor tng456

Generic: PRMT5 Inhibitor TNG456

prmt5 inhibitor tng456: sourced relationships with 1 company · 1 clinical trial tracked.

What we can confirm

1 tracked trial

Tango Therapeutics, Inc. (TNGX)

What it means

Source-backed records connect prmt5 inhibitor tng456 to TNGX; that link alone does not prove the drug works.

What to watch

Watch trial status, endpoints, and the next source-backed update.

BioSniper AIPage evidence connected

Prepared research question

How could prmt5 inhibitor tng456 → TNGX affect its developer, and what evidence supports the link?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence5 indications · 0 study sponsors

Related indications

Non Small Cell Lung Cancer Brain Tumor Glioma, Malignant Lung Cancer Solid Tumor

Study sponsors

No additional listed-company sponsor is linked.

Dated Pipeline Records (1)

Company	Dated record stage	Indication
Tango Therapeutics, Inc. (TNGX) developer · Reported 2026-03-05 · Current development: unknownSource Non Small Cell Lung Cancer	Phase 1/Phase 2	Non Small Cell Lung Cancer

Clinical Trial Registry Records (1)

A Phase 1/2, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, and Preliminary Antitumor Activity of TNG456 Monotherapy and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss

NCT06810544Registry updated 2026-04-13·Phase 1/Phase 2·TNGX

Recruiting

Primary endpoint: Phase 1 Maximum Tolerated Dose

Interventionalopen191 targetStarted 2025-03Completion 2027-0915 sites · United StatesTango Therapeutics, Inc.

Frequently asked questions

Which companies have sourced relationships with prmt5 inhibitor tng456?

prmt5 inhibitor tng456 has dated SEC/FDA relationship records for Tango Therapeutics, Inc..

How many clinical trials involve prmt5 inhibitor tng456?

BioSniper tracks 1 clinical trial involving prmt5 inhibitor tng456.